DNAprint Genomics (DNAG)

[worktoplay]

Brothers...From my admittedly limited research into EPO, there seems to be a number of serious side effects. I suspect that a "Super" EPO may be more prone to adverse events, since several of the side effects associated with commercially available EPO appear to be dose related.

In short, DNAPrint's ability to identify genetic markers predictive of response and predictive of adverse events may be the only way to get that drug to market, thus, the primary reason this drug was made available to them.

Secondarily, however, their work in this area may pay dividends even if their own EPO-EPO drug never reaches the market. Given the side effects associated with existing EPO drugs, there would seem to be a compelling need for a good classifier in the existing EPO market, which itself is $10 Billion and growing.

Of course, this is JMHO.

Later,
W2P